Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Survivorship: Sexual Dysfunction (Male), Version 1.2013 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Denlinger, C. S., Carlson, R. W., Are, M., Baker, K. S., Davis, E., Edge, S. B., Friedman, D. L., Goldman, M., Jones, L., King, A., Kvale, E., Langbaum, T. S., Ligibel, J. A., McCabe, M. S., McVary, K. T., Melisko, M., Montoya, J. G., Mooney, K., Morgan, M. A., O'Connor, T., Paskett, E. D., Raza, M., Syrjala, K. L., Urba, S. G., Wakabayashi, M. T., Zee, P., McMillian, N., Freedman-Cass, D. 2014; 12 (3): 356-363

Abstract

Various anticancer treatments, especially those directed toward the pelvis, can damage blood vessels and reduce circulation of blood to the penis and/or damage the autonomic nervous system, resulting in higher rates of erectile dysfunction in survivors than in the general population. In addition, hormonal therapy can contribute to sexual problems, as can depression and anxiety, which are common in cancer survivors. This section of the NCCN Guidelines for Survivorship provides screening, evaluation, and treatment recommendations for male sexual problems, namely erectile dysfunction.

View details for Web of Science ID 000332777600009

View details for PubMedID 24616541